MRVI
Maravai LifeSciences Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.32
−0.68%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 208.8M | 185.7M | 259.2M | 288.9M | 883.0M |
| Cost of Revenue | 136.5M | 152.4M | 150.9M | 148.7M | 169.0M |
| Gross Profit | 72.2M | 33.4M | 108.3M | 140.2M | 714.0M |
| Operating Expenses | |||||
| R&D Expense | 21.1M | 23.3M | 19.2M | 17.3M | 18.4M |
| SG&A Expense | 152.7M | 171.5M | 161.8M | 151.4M | 129.3M |
| General & Admin Expense | 32.1M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (197.7M) | (154.7M) | 162.9M | 3.2M | (7.8M) |
| Total Operating Expenses | (23.8M) | 40.1M | 343.9M | 171.8M | 139.8M |
| Cost and Expenses | 112.7M | 192.5M | 494.8M | 320.6M | 308.8M |
| Operating Income (EBIT) | 96.1M | (6.7M) | (235.6M) | (31.6M) | 574.2M |
| Non-Operating | |||||
| Interest Income | 20.7M | 23.9M | 27.4M | 27.7M | 2.3M |
| Interest Expense | 24.0M | 27.0M | 47.7M | 45.9M | 20.4M |
| Net Interest Income | (3.2M) | (3.0M) | (20.3M) | (18.2M) | (18.1M) |
| Other Non-Op Income/Expense | (232.6M) | (228.2M) | (25.9M) | 649.4M | (22.7M) |
| Non-Operating Income (excl Interest) | 208.6M | 201.2M | (21.8M) | (695.3M) | 2.3M |
| EBT (Pre-Tax Income) | (136.5M) | (235.0M) | (261.5M) | 617.7M | 551.5M |
| Income Tax Expense | (408.0K) | (4.2M) | (1.9M) | 756.1M | 60.8M |
| Bottom Line | |||||
| Net Income | (77.4M) | (130.8M) | (144.8M) | (119.0M) | 220.2M |
| Earnings from Cont. Ops | (136.1M) | (230.8M) | (259.6M) | (138.4M) | 490.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (77.4M) | (130.8M) | (144.8M) | (119.0M) | 426.3M |
| Per Share | |||||
| Basic EPS | ($0.54) | ($0.91) | ($1.05) | ($0.90) | $1.67 |
| Diluted EPS | ($0.54) | ($0.91) | ($1.05) | ($0.90) | $1.67 |
| Revenue Per Share | $1.41 | $1.28 | $1.88 | $2.19 | $6.71 |
| Shares | |||||
| Basic Shares Outstanding | 148.0M | 145.1M | 137.9M | 131.9M | 131.5M |
| Diluted Shares Outstanding | 148.0M | 145.1M | 137.9M | 131.9M | 131.7M |
| Profitability Metrics | |||||
| EBITDA | (57.2M) | (147.1M) | (156.9M) | 712.4M | 610.0M |
| D&A | 55.3M | 60.9M | 56.9M | 48.8M | 38.1M |
| EBIT | (112.5M) | (208.0M) | (213.8M) | 663.6M | 571.9M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026